CanSino Biologics Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING1
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MCV4 NCT06226714 |
P3 | Active, not recruiting | Meningococcal Meningitis | 840 | 2024-09-26 |
| Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP) NCT05951725 |
P3 | Active, not recruiting | Diphtheria, Tetanus and Acellular Pertussis | 2520 | 2025-04-01 |
| Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1) NCT06857370 |
P3 | Active, not recruiting | Diphtheria, Tetanus and Acellular Pertussis | 780 | 2026-01 |
| Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose NCT06577298 |
P1/2 | Active, not recruiting | Poliomyelitis | 480 | 2026-10 |
| 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M) NCT07600983 |
P1/2 | Recruiting | Streptococcus Pneumoniae Infection | 854 | 2026-11-24 |
| PCV13i NCT07017777 |
P3 | Active, not recruiting | Pneumococcal Infections; Streptococcal Infections | 600 | 2027-02-15 |